| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/05/2007 | US7227022 Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase |
| 06/05/2007 | US7227020 protein kinase inhibitors; asthma, psoriasis, antiinflammatory agents; inflammatory bowel disorders |
| 06/05/2007 | US7227002 Human antibodies that bind human 17-A1/EpCAM tumor antigen |
| 06/05/2007 | US7226945 Estrogen receptor-β ligands |
| 06/05/2007 | US7226944 As antitumor agent |
| 06/05/2007 | US7226940 Such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease |
| 06/05/2007 | US7226921 An enzyme inhibitor of cysteine proteases, a morpholine-4-carboxyamide 1,3,4-oxadiazole derivatives; for treating arthritis, muscular dystrophy, inflammation, tumor, glomerulonephritis, malaria, periodontal disease |
| 06/05/2007 | US7226920 Aminotriazole compounds useful as inhibitors of protein kinases |
| 06/05/2007 | US7226918 DNA-PK inhibitors |
| 06/05/2007 | US7226785 A single-stranded oligonucleotide with a DNA domain having at least one mismatch with respect to genetic sequence to be altered |
| 06/05/2007 | US7226596 Metalloenzymes; antiproliferative agents; anticarcinogenic agents; cancer diagnosis; antisense agents; complementary determining regions |
| 06/05/2007 | US7226595 Conjugated antigen for use as tool in the treatment of cancer |
| 06/05/2007 | US7226586 Biocompatible polymer designed to release nitric oxide; extensively cross-linked polyamine-derivatized divinylbenzene; sustained release, potentiation |
| 06/05/2007 | US7226578 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis |
| 06/05/2007 | CA2411671C Inhibitors of alpha l beta 2 mediated cell adhesion |
| 06/05/2007 | CA2356294C Pharmaceutical compositions for treating bone lesions in multiple myeloma |
| 06/05/2007 | CA2225528C Novel camptothecin analogues, preparation methods therefor, use thereof as drugs, and pharmaceutical compositions containing said analogues |
| 06/05/2007 | CA2214431C Human vegf-specific antisense oligonucleotides |
| 06/02/2007 | CA2565418A1 Dicationic compounds which selectively recognize g-quadruplex dna |
| 05/31/2007 | WO2007062175A2 Spiro-substituted tricyclic heterocycles cxcr3 antagonists |
| 05/31/2007 | WO2007062093A2 Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor |
| 05/31/2007 | WO2007062073A2 Models of metastatic tumors |
| 05/31/2007 | WO2007061978A1 Spirocyclic compounds as hdac inhibitors |
| 05/31/2007 | WO2007061909A1 Thiazoles for the treatment of proliferative disorders |
| 05/31/2007 | WO2007061880A1 Spirocyclic compounds as hdac inhibitors |
| 05/31/2007 | WO2007061130A1 Anti-tumor agent for multiple myeloma |
| 05/31/2007 | WO2007061127A1 Anti-tumor agent for multiple myeloma |
| 05/31/2007 | WO2007061029A1 Therapeutic agent for prostate cancer |
| 05/31/2007 | WO2007061022A1 Mitochondrial function of prohibitin 2 (phb2) |
| 05/31/2007 | WO2007060992A1 Agent for preventing or improving metabolic syndrome or insulin-resistance syndrome |
| 05/31/2007 | WO2007060918A1 Novel memory ctl induction potentiator |
| 05/31/2007 | WO2007060899A1 Application of actin-binding protein to disease associated with cell motility |
| 05/31/2007 | WO2007060811A1 Process for production of fucoxanthinol |
| 05/31/2007 | WO2007060747A1 Galectin-9 induction factor |
| 05/31/2007 | WO2007060715A1 Method of screening interleukin-6 (il-6) signal transduction inhibitor |
| 05/31/2007 | WO2007060686A1 Novel loganin analogues and a process for the preparation thereof |
| 05/31/2007 | WO2007060684A1 An improved process for the isolation of arjunic acid from the bark of the tree terminalia arjuna and the use of this compound in the treatment of cancer |
| 05/31/2007 | WO2007060409A1 L-alanine derivatives |
| 05/31/2007 | WO2007060404A1 PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| 05/31/2007 | WO2007060132A1 N-hydroxyamide derivatives and use thereof |
| 05/31/2007 | WO2007060112A1 Salicylic acid derivatives |
| 05/31/2007 | WO2007060110A1 4-aminopyrimidine-5-thione-derivatives for the treatment of cancer |
| 05/31/2007 | WO2007060028A1 Napthyridine compounds as rock inhibitors |
| 05/31/2007 | WO2007060011A1 Therapy of malignant neoplasias |
| 05/31/2007 | WO2007059997A1 Monoclonal antibodies against claudin-18 for treatment of cancer |
| 05/31/2007 | WO2007059963A1 F,g,h,i and k crystal forms of imatinib mesylate |
| 05/31/2007 | WO2007059872A1 Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents |
| 05/31/2007 | WO2007059821A1 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer |
| 05/31/2007 | WO2007059613A1 Antineoplastic compounds |
| 05/31/2007 | WO2007059574A1 A molecule and chimeric molecules thereof |
| 05/31/2007 | WO2007044015A9 Treating or preventing renal cancer using a dimethane sulfonate |
| 05/31/2007 | WO2007041077A3 Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| 05/31/2007 | WO2007037560A9 Therapeutic or diagnostic application of sgk2 gene |
| 05/31/2007 | WO2007037555A9 Therapeutic or diagnostic application of dusp15 gene |
| 05/31/2007 | WO2007037550A9 Therapeutic or diagnostic application of tsta3 gene |
| 05/31/2007 | WO2007037538A9 Therapeutic or diagnostic application of spo11 gene |
| 05/31/2007 | WO2007037533A9 Therapeutic or diagnostic application of ppp1r3d gene |
| 05/31/2007 | WO2007037532A9 Therapeutic or diagnostic application of srms gene |
| 05/31/2007 | WO2007037514A9 Novel application of heparin-binding epidermal growth factor-like growth factor for medical purposes |
| 05/31/2007 | WO2007030361A3 Benzimidazole thiophene compounds as plk inhibitors |
| 05/31/2007 | WO2007026251A8 Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
| 05/31/2007 | WO2007024294A3 Certain substituted ureas, as modulators of kinase activity |
| 05/31/2007 | WO2007023298A3 Antibodies |
| 05/31/2007 | WO2007021795A3 Compounds and compositions as protein kinase inhibitors |
| 05/31/2007 | WO2007017652A3 Arylakylamines for the treatment of cancer |
| 05/31/2007 | WO2007013896A3 Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
| 05/31/2007 | WO2006138059A3 Treatment of autoimmune disorders with a neurotoxin |
| 05/31/2007 | WO2006113483A3 Methods and compositions for treating or preventing cancer |
| 05/31/2007 | WO2006110496A3 Activation of sodium potassium atpase |
| 05/31/2007 | WO2006109188A3 Composition for treating cancer adapted for intra-tumoral asministration and uses thereof |
| 05/31/2007 | WO2006109091A3 Sensitisation of cancer cells to dna replication inhibitors |
| 05/31/2007 | WO2006074370A3 Agonists and antagonists of tnfrii/cd120b for treatment of immune-related diseases |
| 05/31/2007 | WO2006050732A3 Lna oligonucleotides and the treatment of cancer |
| 05/31/2007 | WO2006042418A9 Antiviral oligonucleotides |
| 05/31/2007 | WO2006031353A3 Vascular endothelial growth factor fusion constructs and uses thereof |
| 05/31/2007 | WO2006015318A3 Antibody conjugated to a drug moiety via a poptidic linker |
| 05/31/2007 | WO2005094802A3 Inhibiting proliferation of neoplastic cells by mlk inhibition |
| 05/31/2007 | WO2002094185A3 Conjugates and compositions for cellular delivery |
| 05/31/2007 | US20070124837 Desaturase genes, enzymes encoded thereby, and uses thereof |
| 05/31/2007 | US20070124826 Method of differentiation from embryo-stem cell of primate to hematogenous cell |
| 05/31/2007 | US20070124825 Use of hepcidin as a regulator of iron homeostasis |
| 05/31/2007 | US20070123699 Peptide conjugate useful for cell nucleus molecular imaging and tumor therapy |
| 05/31/2007 | US20070123580 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 05/31/2007 | US20070123530 e.g. (2-chloropyrimidin-4-yl)-(4-ethyl-3H-thiazol-2ylidene)-acetonitrile,[4-(4-chlorophenyl)-1,3-thiazol-2(3H)-ylidene](2-chloropyrimidin-4-yl)acetonitrile; Jun N-terminal kinase and Glycogen Synthase Kinase 3 inhibitor; antidiabetic, antiinflammatory, anticarcinogenic agent; neurodegenerative diseases |
| 05/31/2007 | US20070123529 Substituted biphenyl compounds |
| 05/31/2007 | US20070123491 Podophyllotoxin derivatives as igf-1r inhibitors |
| 05/31/2007 | US20070123479 single chain antibody construct comprising binding domains specific for human CD3 and human CD19; anticarcinogenic biodrug for treating non-Hodgkin lymphoma |
| 05/31/2007 | US20070122860 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| 05/31/2007 | US20070122428 Genetically modified cholera toxin (CT-CRM) comprising reduced toxicity and enhanced immunological response for use in preparation of vaccines against parasitic infection |
| 05/31/2007 | US20070122412 Eg-vegf nucleic acids and polypeptides and methods of use |
| 05/31/2007 | US20070122407 ISOLATED NUCLEIC ACIDS, VECTORS AND HOST CELLS ENCODING ErbB3 ANTIBODIES |
| 05/31/2007 | DE69133083C5 Behandlung und Vorbeugung von erhöhten Lyso-PAF-Spiegel mediierten mentalen Erkrankungen mit PAF-Antagonisten Treatment and prevention mediated by elevated lyso-PAF mirror mental disorders with PAF antagonists |
| 05/31/2007 | DE102005047616A1 Kombination Combination |
| 05/31/2007 | CA2824517A1 Nuclear receptor binding agents |
| 05/31/2007 | CA2824301A1 F, g, h, i and k crystal forms of imatinib mesylate |
| 05/31/2007 | CA2630848A1 Use of 3-iodo-l-phenylalanine or 4-iodo-l-phenylalanine in the treatment of malignant neoplasia |
| 05/31/2007 | CA2630833A1 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer |
| 05/31/2007 | CA2630805A1 Salicylic acid derivatives |
| 05/31/2007 | CA2630738A1 Immunostimulatory oligoribonucleotides |
| 05/31/2007 | CA2630551A1 N-hydroxyamide derivatives and use thereof |